Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425959 | 0.83 | NPC1 (0.46) | SMN1; SMN2HPGDALDH1A1KDM4EKMT2A | |
| SCHEMBL1558873 | 0.83 | NAMPT (0.45) | KMT2AGAAMEN1LMNANPC1 | |
| SCHEMBL1906809 | 0.81 | HSD17B10 (0.41) | SMN1; SMN2HPGDALDH1A1KDM4EKMT2A | |
| SCHEMBL5481582 | 0.80 | POLB (0.34) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL5476348 | 0.80 | POLB (0.34) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL4985483 | 0.79 | RAB9A (0.50) | SMN1; SMN2HPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5478772 | 0.79 | ALDH1A1 (0.46) | SMN1; SMN2HPGDALDH1A1KDM4EKMT2A | |
| SCHEMBL5481218 | 0.78 | GAA (0.36) | ALDH1A1KDM4EKMT2AGAAMEN1 | |
| SCHEMBL5481198 | 0.77 | TSHR (0.40) | KDM4EHTTTP53 | |
| SCHEMBL12468731 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010146351-A1 | INDOLYLMETHYL-MORPHOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-12-23 | — | — | WO | disclosed |
| US-7595332-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBOTT LABORATORIES (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20070208021-A1 | Phenoxyacetic Acid Derivatives and Drug Comprising The Same | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-09-06 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1731513-A1 | PHENOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1673342-A2 | AMIDES THAT INHIBIT VANILLOID RECEPROT SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBVIE INC. | 2006-06-08 | — | — | US | disclosed |
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2005040121-A2 | AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | PTGS1, PTGER1, TBXA2R | SMN1; SMN2 3713/4885HPGD 80/4885ALDH1A1 185/4885 |
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | TRPV1, OPRL1, AVPR2 | SMN1; SMN2 2485/4885HPGD 622/4885ALDH1A1 222/4885 |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, OPRL1, AVPR1A | SMN1; SMN2 2515/4885HPGD 611/4885ALDH1A1 213/4885 |
| US-20070208021-A1 | Phenoxyacetic Acid Derivatives and Drug Comprising The Same | PPARA, PPARG, PPARD | SMN1; SMN2 4822/4885HPGD 976/4885ALDH1A1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.